88 results about "Host immunity" patented technology

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.

The invention discloses an implantable acellular matrix material and a preparation method thereof, and belongs to the field of biomedical materials. According to the method, natural animal tissues (such as pericardium, achilles tendon or small intestine submucosa) are used as raw materials, a low-temperature chemical combined decellularization treatment technology is adopted, and the method comprises the multi-step synergistic process of pre-cooling soaking balancing, low-temperature enzymolysis, low-concentration surfactant gradient permeation cleaning, low-temperature nuclease degradation, non-crosslinking sterilization and the like. Under the condition that the treatment temperature is strictly kept at 0-8 DEG C, cell components and genetic materials (the residual DNA content is 1t, and the dry weight is 8 ng / mg) are efficiently removed, and meanwhile the natural three-dimensional fine structure of an extracellular matrix (ECM), the integrity of collagen fibrils and key bioactive components (such as glycosaminoglycans (GAGs)) are reserved to the maximum extent. The host immunological rejection reaction of the obtained material is remarkably reduced, host cell ingrowth, vascularization and tissue function reconstruction can be effectively promoted after implantation, and the material is suitable for high-end implantation scenes such as soft tissue repair and regenerative medical stents.

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

The monoclonal antibody specifically binds to CD25, and the conjugate of anti-CD25 antibody are described.The CD25-specific monoclonal antibody and its conjugate do not block the binding of IL-2 to CD25, and induce little or no antibody-dependent cell-mediated cytotoxicity (ADCC).The anti-CD25 antibody and conjugate can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance local host immune response against tumors.

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

This invention belongs to the field of biomedical engineering technology, providing a method for preparing modular bio-ink for cell spheres and its application in the field of myocardial repair therapy. First, a method for preparing stem cell spheres based on microarrays is described. By introducing a protein / polyphenol composite coating onto the cell spheres, a multifunctional armor is created, providing immune protection and immunomodulatory therapy against the host's immune system to reverse the hostile microenvironment and promote the healing process of infarcted myocardial tissue. Second, using microfluidic droplet control technology, gel microspheres loaded with bioactive substances are prepared from biocompatible biomaterials. These microspheres are then densely packed and coated to form cell sphere particle gels. These gels can be used for disease treatment via direct injection or bio-3D printing, showing promising application prospects.

The invention belongs to the technical field of chemical medicines, and particularly relates to a novel triterpene alcohol ferulate compound as well as a preparation method and medical application thereof. According to the invention, oryzanol is used as a raw material, and the new triterpene alcohol ferulate compound is obtained through reversed-phase preparative high performance liquid chromatography and SFC chiral separation and purification. A method and a tool of network pharmacology are used for researching the action mechanism of potential anti-inflammatory and anti-infection related treatment of the new compound. Hierarchical analysis from a global network to a core target reveals a possible action mechanism of the compound in anti-inflammatory and anti-infection, and highlights a regulation mode of a key acting protein. Wherein IGF1R, CTSS, MMP2, BCL2 and other proteins may be core regulatory factors of compound mediated host immune regulation and bacterial drug resistance inhibition, and an important theoretical basis is provided for further research on molecular mechanisms and potential therapeutic targets of compounds in anti-inflammatory and anti-infection related treatment.

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.

The invention provides an optimized and far potent chimeric antigen receptor for its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

T lymphocytes play a key role in the immune response and their functions are intimately linked to metabolic programs. During immune responses, T cells undergo a metabolic reprogramming notably characterized by an increased aerobic glycolysis. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), we demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Conversely, Foxk1 overexpression in T cells enhanced their effector functions in a TCR-dependent manner. In CD8+ T cells, this effect also results into enhanced cancer cell killing capacity in vitro, and improved tumor rejection in vivo. Altogether, these results indicated that Foxk1 is a major regulator of T cell metabolism and thus, of T cell effector functions. Thus, the present invention relates to host immune cells engineered to overexpress a Foxk1 polypeptide and their use of the treatment of cancer.

The invention relates to the technical field of aquaculture, and discloses a treatment method for sleep diseases in fancy carp culture. According to the invention, early-stage rapid intervention is taken as a core, and in combination with the application of the improved suspension and the synergistic effect of the slow-release immune bait, the drug targeting is improved, the stress injury to fish bodies is reduced, the host immunity is enhanced, and the virus diffusion is effectively inhibited; according to the dynamic environment regulation and control technology, through real-time monitoring of water quality parameters and linkage adjustment of drug concentration and oxygenation strategies, environmental adaptability in the treatment process is ensured, drug abuse and residual pollution are reduced, and ecological balance of a water body is maintained; the cross infection of viruses is blocked by a whole-course partition management strategy, and the degradation of drug metabolites is accelerated and the treatment cycle is shortened in combination with the ecological restoration effect of the complex probiotics and the citric acid buffer agent. In addition, a treatment file database is established, the scheme is continuously improved through historical case analysis, the cure rate and operation efficiency are improved, and the comprehensive cost is reduced.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

This invention relates to the field of appropriate immunotherapy for activating the immune response in patients. More specifically, the present invention relates to negative anti-EPO function modulators useful as active ingredients in pharmaceutical compositions for immunomodulatory strategies in therapies (e.g., cancer immunotherapy, therapies for infectious and inflammatory diseases) or for activating the immune system, enhancing cell-based or pharmacological or vaccine-based immunotherapy, and stimulating the immune system response of patients as needed. In particular, the present invention also describes how to restore the immune response in pathological conditions such as cancer and refractory infections, for example, by enhancing and ensuring therapeutic access to immunotherapy strategies by products consisting of EPO pathway inhibitors that can function as active pharmaceutical ingredients in vaccine compositions that stimulate the immune response in cancer, infectious diseases, and inflammatory diseases and be delivered to patients, thereby eliminating "tolerogenic" stimulation.

Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated virus (rAAV) to a subject following administration of a CD19 inhibitor, e.g., an anti-CD19 antibody. The methods described herein can facilitate improved transgene expression, help overcome pre-existing NAbs, and / or permit redosing with the same or substantially similar rAAV or transgene.

The invention discloses a flavonoid compound with an effect of reducing MRSA toxicity and application of the flavonoid compound in neutralizing alpha-hemolysin, and belongs to the technical field of medicinal chemistry. The flavonoid compounds can inhibit secretion of MRSA to alpha-hemolysin (Hla), so that the infection toxicity of MRSA to a host is reduced, and meanwhile, the compounds do not inhibit growth of MRSA, so that generation of drug resistance of MRSA can be greatly reduced. Besides, the compounds can also neutralize alpha-hemolysin (Hla) and have important medical value in clinical diagnosis and treatment, on one hand, damage of MRSA to a host immune system can be reduced, and on the other hand, the compounds are used for treating diseases caused by MRSA and reducing generation of MRSA drug resistance, so that the compounds have important significance in prevention and treatment of MRSA.

The present invention relates to a dual-target double-stranded RNA for treating hepatitis B, and a pharmaceutical composition. The dual-target double-stranded RNA comprises a first double-stranded RNA and a second double-stranded RNA, wherein one of the first double-stranded RNA and the second double-stranded RNA targets the hepatitis B virus (HBV) life cycle, and the other targets a host immune target PD-L1. The double-stranded RNA can simultaneously target the dual targets of HBV and host immune PD-L1, which can inhibit HBV replication while activating human immunity, and is therefore expected to bring about a clinical functional cure.

A new antibacterial peptide of Japanese eel A1 Cath2b 143‑174 and its application, belong to the field of biotechnology. The antibacterial peptide is a Cathelicidin family antibacterial peptide of Japanese eel A1 The 143-174 amino acid fragment of Cathelicidin 2b is named as Cath2b A1 Cath2b 143‑174 , and the amino acid sequence is shown as SEQ ID NO. 3. The antibacterial peptide has high inhibition / killing activity on various aquatic pathogenic bacteria, has excellent thermal stability and salt ion tolerance, and has no obvious toxicity to host cells; it plays a bactericidal role by destroying the bacterial cell membrane, and can also attract host immune cells to enhance immunity. The antibacterial peptide can be applied in the preparation of aquatic animal bacterial disease prevention and control drugs. It can solve the problems of drug resistance and drug residue caused by the abuse of traditional antibiotics, and is convenient to prepare, has strong adaptability, and is suitable for the prevention and control of bacterial diseases of aquatic animals.

The invention provides a polypeptide that is antigenic in a host. The invention also provides a vaccine for use in reducing or preventing Campylobacter colonization in a host. The vaccine comprises a polypeptide of the present invention and / or antibodies against the polypeptide of the present invention. The host may be a human, cow, sheep, goat, and chicken. The invention has particular application for reducing or preventing Campylobacter jejuni colonization in poultry. The invention also provides a vaccine for use in reducing or preventing campylobacteriosis; and a vaccine composition comprising the polypeptide of the present invention; or antibodies raised against the polypeptide of the present invention, in association with a pharmaceutically acceptable vehicle useful for inducing an immune response in a host.

The application discloses a fermented Lactobacillus mui J0273, which is preserved in the Guangdong Microbial Culture Collection Center on March 28, 2024, and has a preservation number of GDMCC No: 64463; the fermented Lactobacillus mui J0273 provided by the application has antioxidant activity, can produce indole-3-methanol, and has good DPPH free radical clearance rate, hydroxyl radical clearance rate, high reducing power, Fe 2+ Chelating capacity, can enhance the antioxidant capacity of the host, regulate the host immune, protect the intestinal barrier, and relieve inflammation.

The present invention relates to modified T cells and methods of making and using the same. Specifically, disclosed herein are modified primary human T cells, and populations thereof, comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and / or B2M genes have been edited to produce off-the-shelf universal CAR T cells from allogeneic healthy donors, the off-the-shelf universal CAR T cells can be administered to any patient while reducing or eliminating the risk of immunological rejection or graft versus host disease, and are not susceptible to T cell inhibition; and methods for allogeneic administration of the cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need thereof.

The invention discloses a construction method of a model for respiratory tract infection caused by inhalation of pathogenic microorganism aerosol, which comprises the following steps: inoculating respiratory tract cells to an upper chamber of a Transwell cell, culturing until a complete cell barrier is formed, and transferring the cell-loaded cell to an exposure cavity; atomizing the pathogenic microorganism suspension into aerosol, and regulating and controlling environmental parameters of the aerosol in real time; introducing the aerosol into an exposure cavity, and enabling the aerosol to be in direct contact with cells in a manner of simulating the inhalation process of the respiratory tract of a human body; and after the exposure is finished, transferring to a porous plate for continuous culture. The invention further discloses application of the model for respiratory tract infection caused by inhalation of the pathogenic microorganism aerosol. The method has the beneficial effects that the model construction process is simple and convenient, the natural infection process can be highly simulated, the method can be used for simulating a bioaerosol exposure scene after specific treatment, and the method is suitable for pathogen invasion mechanism analysis, host immune response research and efficient screening of anti-infection drugs.

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.

The application discloses a combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and a construction method and application of a model thereof. The combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and the kit thereof can accurately and efficiently diagnose the microecological allergic risk of infants and young children of different ages. By integrating multi-dimensional characteristics such as functional gene abundance and KEGG metabolic pathway function activity level, the model can reveal the core mechanism of affecting the host immunity from the perspective of the function of the flora, thereby improving the prediction efficiency and enhancing the biological interpretability of the model. The AUC of the method reaches 0.84 on the test set, indicating that the method has good ability to distinguish allergic and non-allergic individuals. The models of different age groups all have high consistency, proving that the method is stable and reliable and can meet the accuracy requirements of clinical auxiliary decision-making.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

This invention discloses a lncRNA associated with sheep resistance to F17 Escherichia coli diarrhea, the nucleotide sequence of which is shown in SEQ ID NO.1. Through high-throughput sequencing and in vitro validation experiments, this invention discovered that DRB1-AS1 is induced to express during F17 Escherichia coli infection of the sheep small intestine, participating in the host immune protection mechanism during the occurrence and development of sheep diarrhea. It demonstrates that downregulation of DRB1-AS1 expression can reduce the adhesion resistance of sheep primary small intestinal epithelial cells to F17 Escherichia coli. The preparation and application methods of DRB1-AS1 in the prevention or treatment of sheep F17 Escherichia coli diarrhea, anti-inflammatory drug development, or sheep diarrhea resistance breeding have extremely high market implementation potential.

A nanoagonist, and a preparation method and use thereof are provided, belonging to the technical field of nanoscale biomedicine. The nanoagonist is formed by self-assembly of a transformable peptide, where the transformable peptide includes a targeted antimicrobial peptide, a functionalized self-assembling peptide, an FcγR recognition peptide, and a lipase-responsive hydrophobic molecule that are coupled in sequence. The functionalized self-assembling peptide can control the FcγR recognition peptide to flip toward a surface of a target pathogen during secondary self-assembly, and the target pathogen is a pathogen targeted and bound by the targeted antimicrobial peptide. The nanoagonist combines externalization of the FcγR recognition peptide that can be guided during the secondary self-assembly with FcγR-mediated endocytosis, and a nanoagonist is developed for the first time that takes into account both pathogen clearance and host immune function repair.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.